Saghmos Therapeutics
June 16, 2025
Company Presentation
Cardiovascular
Saghmos Therapeutics is a privately held biopharmaceutical company developing ST-62516 (trimetazidine) to reduce the risk of Major Adverse Cardiac and Kidney Events (MACKE) after percutaneous coronary intervention (PCI) procedures. The drug is poised to enter a Phase 3 study that will be conducted by Duke Clinical Research Institute at 100+ sites globally. Trimetazidine has previously been used outside the US in a cardiac indication, so there is robust efficacy and safety data in support of the indication. Cardiac and kidney complications after PCI represent an area of significant unmet medical need, with no approved pharmacological agents. With one million PCI procedures annually in the US, this is a multi-billion dollar opportunity.
Company HQ City:
Greenwich
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
ST-62516 (trimetazidine)
CEO
Anna Kazanchyan, M.D.
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
ST-62516
When you expect your next catalyst update?
Initiation of Phase 3 study
What is your next catalyst (value inflection) update?
Undisclosed
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}